openPR Logo
Press release

Dengue Vaccines Market Globally Expected to Drive Growth through 2026

01-23-2017 12:26 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Dengue Vaccines Market Globally Expected to Drive Growth

Dengue is a mosquito-born flavivirus disease and causes dengue fever characterized by severe headache, skin rash, debilitating muscle, joint pain leaving a feverish feeling. The dengue virus is also called as ‘breakbone fever’ due to the symptoms it causes. The symptoms for dengue start appearing in the span of 3-14 days and can infect infants, young children and adults. Dengue has emerged as one of the critical vector-borne diseases especially in tropical and subtropical regions of the world. The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur registered in Mexico in December, 2015. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine which was evaluated as a 3 dose series 0/6/12 month schedule in Phase III clinical studies. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Along with the developments in dengue vaccines additional technological approaches, such as virus-vectored and VLP-based vaccines, are held under evaluation in preclinical studies for further advancements.

The development for dengue vaccine had begun by 1929 but was delayed due to the incomplete knowledge of the diseases. Sanofi Pasture first approved the vaccine for dengue in 2015 and integrated dengue prevention reducing the mortality rate by almost 50%. WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed CYD-TDV in April 2016 and recommended countries to introduce the vaccine through its Global dengue prevention and Control Strategy (2012-2020).

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1763

The drivers for dengue vaccine market include growing healthcare concerns, increase in mortality rate because of dengue fever. And the challenges faced by the scientist in developing this vaccines were majorly due to the complexity of the dengue virus, expensive trials and time to develop them. After the introduction of Dengvaxia (CYD-TDV), five additional candidates are I clinical trials. The prices for dengue vaccines are much higher but due to government intervention the vaccine are sold on discounted prices in most countries. In March 2016, Dengvaxia was licensed in Mexico, the Philippines, Brazil and El Salvador for effective prevention against dengue from all four serotypes which are mostly found in individuals of age 9-45 years living in endemic areas.

According to WHO (World Health Organization) dengue epidemics are being reported every year from more than 100 endemic countries causing 50-100 million dengue infections worldwide annually. In the years 2010, 2013 and 2015, nearly 2.4 million cases of dengue had been reported indicating the sharp increase in the number. It was estimated 500 000 people with severe dengue require hospitalization each year and from them 2.5% of those affected die each year. The dengue vaccine is being produced in in France in dedicated manufacturing site including a full-scale production capacity of 100 million of vaccine doses annually.

In 2016, Philippines had registered to have the highest incidence of confirmed dengue among the 10 endemic countries which had participated in clinical efficacy studies for the vaccine. In April 2016, the first public dengue immunization program was started in the Philippines. The major launch event which was hosted by the Department of Health (DoH) of the Philippines, which lists the details about the country’s plan of vaccinating about 1 million public school children and was shared with the international and national press during the event. Where in February, Sanofi Pasteur’s dengue vaccine was firstly made available for the private sector vaccination in the Philippines

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1763

In the history of global burden of diseases, dengue which bears about 70% of it had an optimism after the first approval of the vaccine. Due to the developments in the recent years, pharmaceutical companies have started making effort in developing dengue vaccine and have registered their products for clinical trials. Companies such as GlaxoSmithKline plc, Merck & Co., Inc. and Takeda Pharmaceutical Company Ltd. are each at different stages in developing the vaccines for dengue.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Press: press@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dengue Vaccines Market Globally Expected to Drive Growth through 2026 here

News-ID: 419092 • Views:

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute

All 5 Releases


More Releases for Dengue

Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240 The report provides a comprehensive analysis of company profiles listed below: - Sanofi - Takeda Dengue Vaccines Market Segment by
Dengue Fever - Pipeline Review, H1 2018
HTF Market Report released a new research document of 158 pages on industry titled as 'Dengue Fever - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as GeneSegues , GlaxoSmithKline , Globavir Biosciences , Immunotope etc The report will help you gain market insights, future trends and growth prospects for forecast period. Request a sample report @
Dengue Fever Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H1 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape. Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It
Dengue Vaccines Market - Global Insights, 2016-2024
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by
Dengue Vaccine Market to be Driven by Rising Prevalence of Dengue and Increasing …
Dengue is a mosquito-borne infectious disease affecting humans and animals caused by dengue virus belonging to the Flaviviridae family and genus Flavivirus. Dengue is typically transmitted from human to human through the bite of an infected aedes aegypti mosquito. Symptoms of dengue include high fever, headache, fatigue, muscle pain, diarrhea, anemia, skin rashes and vomiting. Severe dengue can cause yellow skin, seizures, coma, or death. Dengue has high mortality rate
Dengue Vaccine Market to be Driven by Rising Prevalence of Dengue and Increasing …
Dengue is a mosquito-borne infectious disease affecting humans and animals caused by dengue virus belonging to the Flaviviridae family and genus Flavivirus. Dengue is typically transmitted from human to human through the bite of an infected aedes aegypti mosquito. Symptoms of dengue include high fever, headache, fatigue, muscle pain, diarrhea, anemia, skin rashes and vomiting. Severe dengue can cause yellow skin, seizures, coma, or death. Dengue has high mortality rate